Author

M. M. Pomerantz

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 4 Research Focus:differential expression· 3 Approach:statistical model· 3 Assay:bulk RNA-seq· 2 Research Focus:chromatin & epigenetic regulation· 2 Approach:experimental assay· 2 Research Focus:gene regulatory network inference· 2 Assay:whole-genome sequencing· 2

Frequent Co-Authors

M. L. Freedman· 3 shared B. Pasaniuc· 2 shared C. Bell· 2 shared E. O'Connor· 2 shared J.-H. Seo· 2 shared L. Ellis· 2 shared M. Brown· 2 shared P. S. Nelson· 2 shared

Activity by Year

2019-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 39 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

M. L. Freedman

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Analysis of evolutionary dynamics and clonal architecture in prostate cancer

J. Conway, A. K. Tewari, S. Y. Camp, S. Han, J. Crowdis, M. X. He, Y. A. Nyame, S. H. AlDubayan, N. Schultz, Z. Szallasi, M. M. Pomerantz, M. L. Freedman, L. Fong, P. S. Nelson, M. Brown, , E. Van Allen

This study analyzes prostate cancer clonal architecture and evolutionary dynamics in 845 tumors, finding that Black patients have more monoclonal tumors but higher recurrence rates, and identifies new mutational signatures linked to subclones.

bioRxiv · Mar 23, 2023 · PreprintCancer Biology

Germline determinants of the prostate tumor genome

K. E. Houlahan, J. Yuan, T. Schwarz, J. Livingstone, N. S. Fox, W. Jaratlerdsiri, J. van Riet, K. Taraszka, N. Kurganovs, H. Zhu, J. Sietsma Penington, C.-H. Jung, T. N. Yamaguchi, J. Jiang, L. E. Heisler, , P. C. Boutros

The paper identifies germline-determined quantitative trait loci (dQTLs) that influence somatic mutational features in prostate cancer, revealing their impact on tumor epigenome, transcriptome, and proteome.

bioRxiv · Nov 16, 2022 · PreprintCancer Biology

Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancer

S. C. Baca, D. Y. Takeda, J.-H. Seo, J. Hwang, S. Y. Ku, R. Arafeh, T. Arnoff, S. Agarwal, C. Bell, E. O'Connor, X. Qiu, S. Abu Alaiwi, R. I. Corona, M. A. S. Fonseca, C. Giambartolomei, , M. L. Freedman

The paper identifies FOXA1 reprogramming in NEPC and shows its role in maintaining NE lineage features through epigenomic profiling.

bioRxiv · Oct 23, 2020Cancer Biology

Targeting EZH2 Increases Therapeutic Efficacy of Check-Point Blockade in Models of Prostate Cancer

A. V. Sheahan, K. L. Morel, D. L. Burkhart, S. C. Baca, D. P. Labbe, K. Roehle, M. Heckler, C. Calagua, H. Ye, P. Galbo, S. Panja, A. Mitrofanova, A. A. Hamid, A. S. Kibel, A. D. Choudhury, , L. Ellis

This study shows that inhibiting EZH2 enhances the effectiveness of PD-1 checkpoint inhibitors in prostate cancer by increasing PD-L1 expression and immune cell infiltration.

bioRxiv · Aug 8, 2019 · PreprintCancer Biology